| Chapter title |
Male hormonal contraception.
|
|---|---|
| Chapter number | 11 |
| Book title |
Fertility Control
|
| Published in |
Handbook of experimental pharmacology, September 2010
|
| DOI | 10.1007/978-3-642-02062-9_11 |
| Pubmed ID | |
| Book ISBNs |
978-3-64-202061-2, 978-3-64-202062-9
|
| Authors |
Nieschlag E, E. Nieschlag, Nieschlag, E. |
| Abstract |
The principle of hormonal male contraception based on suppression of gonadotropins and spermatogenesis has been established over the last three decades. All hormonal male contraceptives use testosterone, but only in East Asian men can testosterone alone suppress spermatogenesis to a level compatible with contraceptive protection. In Caucasians, additional agents are required of which progestins are favored. Current clinical trials concentrate on testosterone combined with norethisterone, desogestrel, etonogestrel, DMPA, or nestorone. The first randomized, placebo-controlled clinical trial performed by the pharmaceutical industry demonstrated the effectiveness of a combination of testosterone undecanoate and etonogestrel in suppressing spermatogenesis in volunteers. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 1 | 20% |
| Student > Doctoral Student | 1 | 20% |
| Unknown | 3 | 60% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 1 | 20% |
| Medicine and Dentistry | 1 | 20% |
| Unknown | 3 | 60% |